London, UK – 24 January 2024. A clinical validation study of Digistain in 801 patients with ER-positive, HER2-negative early breast cancer (median follow-up 12.7 years) was published in Breast Cancer Research and Treatment. The study reports the prognostic performance of the Digistain Prognostic Score; please see the publication for full results.
Digistain Launches First International Lab in South Africa
In our ongoing effort to bring accessible cancer diagnostics to the regions that need them most, we are proud to announce the official launch of
